Continue to enjoy the positive fundamental progress, absence of dilution outside of Keysight which brings with it its own positive narrative.
i would have thought by this stage of the trials that a few well paid neurologists / radiologists would have seen/heard about the progress (or maybe used the device directly) and taken a punt on it - with the low shares on offer, would have expected a more than a few ‘pops’ in the share price over the recent period. Outside of the initial Keysight excitement, it’s been tough to watch.
am I right to assume some level of buzz / literal buy-in from the medical community as trials progress in a positive fashion? Or is there some kind of non-disclosure agreement in place that means I’m barking up the wrong tree?
EMV Price at posting:
$1.83 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)